江中药谷智能化生产车间 江中药谷液体制剂车间 江中药业研发实验室 福事特智造机械 福事特自动生产线 福事特绿色厂区 耐普矿机江西上饶总部 耐普矿机 三鑫医疗中空纤维血液透析膜纺丝线 三鑫医疗实验室 50亿盒爆款背后有座2000亩氧吧 江中药业"以智提质"焕新"千年草本" ◎记者 王凯丰 山林环抱,湖水澄碧……走进位于江西省南昌市的华润江中湾里制造基地（江中药谷），仿佛置身于一 座湿地森林公园、"天然氧吧"，2000余亩的厂区内，大部分区域被森林与湖泊覆盖，吸引了不少野生小 动物在此栖息繁殖。很难想象，这里是一家中医药工厂，国内市场上超九成的健胃消食片便产自这里。 "肚子胀不消化，家中常备江中牌健胃消食片。"即便多年过去，提及这句朗朗上口的广告词，仍能瞬间 勾起几代人的共同回忆。 作为国内首个年销售额过10亿元的中药爆款单品，江中牌健胃消食片已连续21年蝉联"中国非处方药产 品榜"中成药消化类第一名，累计销量突破50亿盒。 在液体制剂车间内，一台形似高压锅的设备格外引人注目。据介绍，这台超声清洗装置能够有效去除原 料农药残留。在公司自主研发的中药吊篮式循环提取MVR浓缩集成技术支持下，该设备能够精准去除 10万 ...

| 序号 | 代码 | 简称 | 車日涨幅 | 年内涨幅 | 股息率(近12个 | | --- | --- | --- | --- | --- | --- | | | | | (%) | (%) | 月) (%) | | 1 | 002083.SZ | 录日股份 | 9.99 | 143.49 | 1.37 | | 2 | 600211.SH | 西藏药业 | 1.86 | 35.24 | 3.99 | | 3 | 601686.SH | 友发集团 | 1.82 | 29.54 | 4.38 | | 4 | 603408.SH | 建霖家居 | 1.73 | 7.82 | 5.74 | | 5 | 601988.SH | 中国银行 | 1.39 | 10.34 | 3.86 | | 6 | 688516.SH | 奥特维 | 1.14 | 10.60 | 4.70 | | 7 | 600351 SH | 亚宝药业 | 1.00 | 21.34 | 4.30 | | 8 | 002895.SZ | 川恒股份 | 1.00 | 66.43 | 3.63 | | a | 603967.SH | 中创物流 | 0.9 ...

消费风起，布局医药消费正当时 20251111 摘要 沃伍生物股价表现良好，方盛制药和佐力药业股价接近历史新高，具备 投资机会，这些公司拥有收入、利润和现金流，是优质投资标的。 医疗服务行业受 DRG 政策和消费环境影响业绩较弱，但预计 2026 年将 改善。供给端收缩，民营医院扩张受阻，并购或新增大医院或改善表观 数据。 眼科领域关注爱尔、华夏和普瑞，预计 2026 年一季度屈光业务将释放 业绩。白内障筛查明年有望好转，当前股价底部具备投资价值。 通策医疗紫金港总院和义乌浙中总院开业，红云分院进展放缓，亏损减 少。预计 2026 年收入和利润增速将提升，公司处于拐点位置。 固生堂去年快速扩张，今年新增多家分院并进入天津市场，收购深圳天 元医院。三季度利润增速高于收入增速，全年业绩预期超 30%，估值偏 低。 海吉亚受医保影响较大，但目前处于底部，公司持续增持。明年无锡、 常熟新医院开设及重庆、西安医院增长有望修复表观数据。 流感相关企业如国邦、普洛药业和联邦制药产能利用率大幅提升，满产 满销。若流感持续爆发，可能出现短缺和涨价，四季度及明年一季度业 绩有望显著增长。 我们坚定看好医药创新，包括创新药及其产业 ...

Core Insights - Recently, the establishment of China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was announced, with a total investment of 1 billion RMB, focusing on venture capital in the pharmaceutical sector [1] Group 1: Fund Establishment - The fund is executed by China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) and has a registered capital of 1 billion RMB [1] - The fund's partners include Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Investment Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) [1] - This new fund will focus on the main responsibilities of the pharmaceutical health sector and strategic emerging industries [1]

Core Insights - Recently, China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was established with a capital contribution of 1 billion yuan [1] - The fund's business scope includes venture capital, specifically limited to investments in unlisted companies [1] - The fund is jointly funded by several companies, including Fosun Pharma, Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical [1] Company Contributions - Fosun Pharma's wholly-owned subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is a key contributor to the fund [1] - Other contributors include Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical, indicating a collaborative investment approach among major players in the pharmaceutical industry [1] Investment Focus - The fund is specifically focused on venture investments, which suggests a strategic interest in supporting early-stage pharmaceutical companies [1] - The emphasis on unlisted companies may provide opportunities for high-growth potential investments within the pharmaceutical sector [1]

| | 早,河 都在用的商业查询工具 | 查老板 查风险 | | | | | | --- | --- | --- | --- | --- | --- | --- | | | 国家上加拿球中国发言少了书籍 | 华润(成都)医药产业股权投资基金合伙企业(有限合 8 | 天眼一下 | ■ 应用 ▼ | 商务合作 企业级产品、 ■ 开通会 | | | 基本信息 283 | 法律诉讼 | 经营风险 | 经营信息 | 公司发展 | 知识产权 | | | 工商信息 历史工商信息0 | | | | | | | | 企业名称 | 华润(成都)医药产业股权投资基金合伙企业(有限合伙) | | | | | | | 执行事务合伙人 | 华润医药科技(成都)合伙企业 家庭 医药 | 登记状态 7 | 存续 | | 天眼评分 2 | 97 9 | | | (有限合伙) | 成立日期 | 2025-11-07 | | | | | 统一社会信用代码 2 | 91510100MAK126UR31 | 出资额 | 100000万人民币 | | 立創 | | | 工商注册号 | 510109202136044 | 纳税人识别号 2 | 91510 ...

Core Insights - Recently, China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was established with a capital contribution of 1 billion RMB, focusing on venture capital [1] Group 1: Fund Establishment - The fund's executive partner is China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) [1] - The fund is co-funded by Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Strategic Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) with Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. and Chengdu state-owned enterprises [1] - The focus of this new fund will be on the pharmaceutical health main business and strategic emerging industries [1]

出租车电子计价器属于国家实行强制检定的计量器具，其计量准确与否直接关系乘客切身利益。 在天津市市场监管委查处出租车计价器作弊系列案中，26辆出租车的电子计价器装有作弊装置，且 其中16台电子计价器超期未检定；26辆出租车的司机利用作弊装置增加计价里程，多收乘车费。天津市 市场监管委依据计量法有关规定，没收相关出租车司机涉案电子计价器及附带作弊装置共计26套、罚款 合计3.1万元，并将非法安装作弊装置的相关当事人移交公安机关。 生产销售侵犯注册商标专用权的商品，不仅侵犯商标权利人利益，也损害公平竞争的市场秩序。 出租车电子计价器作弊、生产销售假冒"亚朵星球"枕头、非法改装电动自行车进行销售……市场监 管总局5日公布2025"守护消费"铁拳行动第二批典型案例。 在上海市奉贤区市场监管局查处上海茗步信息科技有限公司侵害消费者权益案中，当事人在销售话 费、外卖会员、影视平台月卡等权益包产品过程中，要求消费者开通会员时勾选同意增值权益服务协 议，其中含有"用户购买会员服务后……系统将在会员到期前自动续费"等条款，并在自动续费前未通过 任何方式提请消费者注意。市场监管部门依据消费者权益保护法等有关法规，给予当事人警告并罚 ...

新华社北京11月5日电题：市场监管总局公布"守护消费"铁拳行动第二批典型案例 新华社记者赵文君 出租车电子计价器作弊、生产销售假冒"亚朵星球"枕头、非法改装电动自行车进行销售……市场监 管总局5日公布2025"守护消费"铁拳行动第二批典型案例。 出租车电子计价器属于国家实行强制检定的计量器具，其计量准确与否直接关系乘客切身利益。 在天津市市场监管委查处出租车计价器作弊系列案中，26辆出租车的电子计价器装有作弊装置，且 其中16台电子计价器超期未检定；26辆出租车的司机利用作弊装置增加计价里程，多收乘车费。天津市 市场监管委依据计量法有关规定，没收相关出租车司机涉案电子计价器及附带作弊装置共计26套、罚款 合计3.1万元，并将非法安装作弊装置的相关当事人移交公安机关。 生产销售侵犯注册商标专用权的商品，不仅侵犯商标权利人利益，也损害公平竞争的市场秩序。 在江苏省南通市通州区市场监管局查处生产销售侵犯他人注册商标专用权的枕头案中，现场查获印 有"亚朵星球"等注册商标的枕头543件、各类包装盒2206件、印有商标的产品吊牌17245件，经商标权利 人鉴定，均为侵权产品。当事人在未取得商标权利人授权的情况下，擅自生产 ...

Core Viewpoint - The article discusses the establishment of significant investment funds by China Resources Double Crane and China Resources Pharmaceutical, focusing on synthetic biology and innovative pharmaceuticals, indicating a strategic shift towards high-growth sectors in the biomanufacturing industry [2][3]. Investment Fund Establishment - China Resources Double Crane and China Resources Pharmaceutical announced the formation of a 500 million RMB fund, with a commitment of 123 million RMB from the group, representing 24.6% of the total fund [2]. - China Resources Double Crane also established the "China Resources Double Crane Industry Fund," committing up to 83 million RMB, approximately 16.6% of the total fund, aimed at optimizing strategic layout in synthetic biology [3]. Collaboration and Partnerships - The funds involve collaboration with local governments and multiple investors, including 11 limited partners (LPs) such as various China Resources entities and Chengdu local government funds, collectively forming a 1 billion RMB investment fund [3][4]. - The partnership includes significant contributions from local government funds and private enterprises, showcasing a collaborative approach to investment in the biomanufacturing sector [4]. Strategic Focus on Synthetic Biology - China Resources Double Crane has previously invested 502 million RMB to acquire a 50.11% stake in Shenzhou Biology, enhancing its capabilities in the biomanufacturing field [5]. - The establishment of a synthetic biology research institute in 2023 indicates a commitment to developing a comprehensive R&D, pilot testing, and industrialization system, focusing on industrial enzymes and microorganisms [5]. Research and Development Initiatives - The company has developed seven technology platforms in synthetic biology, with over ten ongoing projects, leveraging expertise from seasoned scientists with experience in major corporations [5].